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Introduction 
Patients with migratory infiltrates on serial chest radio- 
graphs are rare. Migratory infiltrates are generally believed 
to represent simple pulmonary eosinophilia (Loeffler’s 
syndrome), although bronchiolitis obliterans-organizing 
pneumonia (BOOP) may also present in this way (1). In the 
case of women undergoing breast surgery followed by 
chemotherapy and radiotherapy, we are only aware of cases 
with migratory pulmonary infiltrates diagnosed as BOOP 
(2,3). At present it is known that radiation therapy and 
chemotherapy may give rise to pulmonary complications. 
Alveolar septal thickening and interstitial fibrosis are com- 
mon after chemotherapy (45). Pneumonitis is the main 
complication of radiation therapy, occurring 4-12 weeks 
after treatment has been completed. Pneumonitis is more 
frequent when chemotherapy is received before radiation 
therapy (4). 
Case Report 
A 65-year-old non-smoking woman underwent breast sur- 
gery for a ductal carcinoma of the right breast (stage II) in 
August 1994. She then received six cycles of chemotherapy 
with 600 mg m - * cyclophosphamide, 10 mg m - 2 mithox- 
anthrone and 600 mg m - 2 fluorouracil. She completed 
chemotherapy in May 1995. She underwent radiation 
therapy between June and July 1995. External radiation, 
using photon X, with 50 Gy total (180 cGy per fraction) 
was given over the tumoral zone, the axilar area and the 
upper clavicular and right internal mammary ganglionary 
chain. No infection, neoplastic disease, thrombosis, inhala- 
tion toxicity or connective tissue disease were identified, 
only a calcified hydatid liver cyst being found. In July 1995, 
after completion of her radiation therapy, the patient 
developed fever and a dry cough. A combination of anti- 
biotics and mucolytics was given for 3 weeks, but this 
resulted in no clinical improvement. The patient developed 
progressive dyspnoea on exertion and was admitted in 
November 1995. On examination, the patient’s oral tem- 
perature was 37.5”C and right lung inspiratory crackles 
were heard. Cardiac sounds were normal. The abdomen 
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PLATE 1. Chest roentgenogram showing airspace infil- 
trates in right upper and middle lobes. 
was free of organomegaly, and no peripheral adenopathy 
was found. The right breast scar was painless and the left 
breast was normal. Digital clubbing was absent. A chest 
roentgenogram showed airspace infiltrates in the right 
upper and middle lobes (Plate 1). High resolution computed 
tomography (HRCT) confirmed airspace opacities in the 
right upper and middle lobes. The lung function test 
showed FVC= 1.740 1 (77%) FEV,= 1.440 1 (77%) and 
FEV,/FVC=83%. Carbon monoxide transfer was 63% of 
the predicted value. Arterial blood gases at rest showed 
arterial oxygen tension (PaO,) at 62 mmHg and arterial 
carbon dioxide tension (PaCO,) at 36.4 mmHg. Haemo- 
globin was 11.7 mg dl ~ i; the white blood cell count 
revealed 7.2 x lo3 with 69% neutrophils, 22% lymphocytes, 
4% monocytes and 3% eosinophils, and the platelet count 
showed 343 x 103. The l-h erythrocyte sedimentation 
rate was 78. Total proteins, albumin, immunoglobulins, 
immune antibodies and rheumatoid factor were normal. 
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PLATE 2. Alveolar septal thickening with fibrosis 
(haematoxilin-eosin, x 375). 
PLATE 3. (a) Normal large bronchiole. (b) Small bronchi- 
ole showing a chronic inflammatory infiltrate in its wall 
(haematoxilin-eosin, x 375). 
Investigations for micro-organisms in sputum were nega- 
tive. Fibre-optic bronchoscopy showed a normal bronchial 
tree. Bronchoalveolar lavage (BAL) was performed on one 
segment of the middle lobe. High lymphocyte cell counts 
suggested alveolitis. A careful search for pathogens in the 
BAL fluid was negative. Transbronchial biopsy afforded a 
small sample of normal lung tissue. Surgical biopsy was 
performed under videothoracoscopy. Histological findings 
revealed alveolar septal thickening with fibrosis (Plate 2). 
The large bronchioles were normal [Plate 3(a)] while the 
small ones showed a chronic inflammatory infiltrate in their 
walls [Plate 3(b)]. No obliteration of respiratory bronchi- 
oles was found. The patient was discharged from the 
hospital in November 1995. Two months later she was 
doing well, although she referred to dyspnoea on exertion. 
The l-h sedimentation rate was 51. Arterial blood gases at 
rest showed PaO, at 61 mmHg and PaCO, at 41 mmHg. A 
chest roentgenogram showed airspace infiltrates in the left 
upper lobe and small residual linear opacities in the right 
upper and middle lobe (Plate 4). HRCT confirmed the 
airspace opacities. The patient was admitted again in 
January 1996. A second fibre-optic bronchoscopy showed a 
normal bronchial tree. BAL fluid was negative for patho- 
PLATE 4. Chest roentgenogram showing airspace infil- 
trates in left upper lobe and small residual linear opacities 
in right upper and middle lobe. 
gens and malignant cells. Transbronchial biopsy of the 
apical segment of the left upper lobe showed interstitial 
fibrosis. A diagnosis of migratory pulmonary infiltrates 
with pneumonitis secondary to chemotherapy and/or 
radiation therapy was given. Treatment with 32 mg day ~ ’ 
methylprednisolone that was progressively tapered off 
resulted in rapid clinical improvement and complete reso- 
lution of airspace opacities (Plate 5). 
Discussion 
Patients with breast cancer are frequent, and most of them 
receive chemotherapy and radiation therapy after surgery, a 
clinical syndrome of pulmonary toxicity developing in a 
substantial number of them. Cyclophosphamide, a drug 
commonly used in chemotherapy protocols, has been 
associated with significant pulmonary toxicity; in particu- 
lar, with interstitial fibrosis (4). Additionally, the com- 
pound has been shown to cause interstitial fibrosis in 
experimental animals (6,7). In rats, cyclophosphamide 
increases the deposition of collagen in lung tissue and the 
production of oxidants by macrophages (8). Radiation 
therapy appears to exacerbate pre-existing cyclophospha- 
mide toxicity. In several patients that had received cyclo- 
phosphamide and radiation therapies, Todd et al. (5) found 
increased dyspnoea and coughing. CT scans of the chest at 
this time also showed airspace opacities in the lung included 
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PLATE 5. Chest roentgenogram showing almost complete 
resolution of opacities. 
within the radiation tangent. Therefore, radiation therapy, 
although it does not seem to be a primary cause of the 
toxicity syndrome, appears to exacerbate pre-existing drug 
toxicity. 
In our case, the airspace lung infiltrates were first 
observed in the right lung (included within the radiation 
tangent). During the evolution of the disease they were also 
seen in the left lung. In this sense, we report here a case of 
migratory pulmonary infiltrates as a probable complication 
of the treatment of patients with breast carcinoma. Few 
disease processes have been described in which fleeting or 
migratory infiltrates are common. These are mainly seen in 
syndromes associated with pulmonary eosinophilia, para- 
sitic infection, allergic bronchopulmonary aspergillosis, 
Churg-Strauss vasculitis and hypersensitivity to drugs (9). 
In our case, although the clinical and radiological aspects 
were reminiscent of BOOP, surprisingly the histopathologi- 
cal diagnosis was alveolar septal inflammation and fibrosis, 
compatible with usual interstitial pneumonia (10) and also 
with radiation pneumonitis (11). This diagnosis seems to 
render our case different from those reported by Bayle et al. 
(2) and Crestani et al. (3). These latter authors reported 
several cases of women receiving breast radiation therapy 
following surgery for breast carcinoma who were diagnosed 
as having BOOP. The main difference between these studies 
and our own report is that our patient received cyclophos- 
phamide after surgery but before radiation therapy. 
Accordingly, treatment with cyclophosphamide might have 
been the cause of the pulmonary toxicity and the radiation 
therapy might have potentiated the drug toxicity. BOOP 
changes normally appear in the mid-course of disease after 
radiation injury of the lung, followed by fibrosis without 
BOOP after 9-12 months (9). These data differ from our 
own since in our patient a histological picture of alveolar 
septal thickening and fibrosis was discovered after only 4 
months of radiation (although it should be noted that we do 
not know when and how these findings developed first after 
the radiation). Nevertheless, we cannot exclude the possi- 
bility that our case might also reflect a later (postBOOP) 
fibrosis stage of the radiation injury, accelerated by cyclo- 
phosphamide treatment. As in BOOP cases, our patient 
also responded properly to corticosteroid therapy. It has 
been proposed that corticosteroid would interrupt an 
inflammatory cascade triggered by oxidant-due injury to 
epithelial and endothelial cells (5). 
In conclusion, we suggest that adjuvant therapy for 
breast cancer (chemotherapy with cyclophosphamide and 
radiation therapy) may produce migratory pulmonary infil- 
trates with a histopathological picture of toxic pneumonitis 
with interstitial fibrosis. 
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Introduction 
Diffuse panbronchiolitis (DPB) is a disease with chronic 
inflammation that is exclusively located in the region of the 
respiratory bronchioles (1). The pathological features of 
this disease are characterized by a thickening of the wall of 
the respiratory bronchioles due to the infiltration of lym- 
phocytes, plasma cells, and histiocytes (1). The disease is 
prevalent in Mongolians and its prognosis is considered to 
be poor when not properly treated. Although DPB has been 
treated with corticosteroids, most patients ultimately suffer 
from a colonization of Pseudomonas aeruginosa. To avoid 
such a complication, ‘low-dose and long-term’ erythromy- 
tin treatment has been introduced as an effective regimen 
for DPB, but the effectiveness of this treatment still remains 
to be elucidated (2). 
Case Report 
A 23-year-old man was admitted to the hospital because of 
an exacerbation of a productive cough, and a fever of 
38.6”C. He had a long history of cough, purulent sputum, 
and paranasal sinusitis beginning in his youth. The patient 
had a reddish complexion and complained of dyspnoea. 
However, he had no history of bronchial asthma. The chest 
was symmetric, and normally resonant. On auscultation, 
scattered rales and rhonchi were heard, mainly in the lower 
lung fields. A haematological examination showed the 
white blood cell count to be 18 000 yl - ‘, with 87% 
neutrophils, 13% lymphocytes. The value of the C-reactive 
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protein (CRP) was 4.4 mg dl - ‘. The blood chemistry find- 
ings were all within the normal limits except for a slightly 
elevated y-globulin (21.7%). His IgE titre was within the 
normal limit. A chest X-ray showed a nodular and reticular 
shadow predominantly located at the bilateral lower lung 
fields associated with the tram line, thus suggesting 
bronchiectatic changes. Computed tomography (CT) of 
the thorax exhibited diffusely disseminated fine nodular 
shadows at the bilateral lower lung fields and bronchiectatic 
changes in the left lower lobe (Plate 1). His vital capacity 
was 2970 ml, 69% of the predicted value and FEV,, 69% of 
his forced vital capacity. The PaO, was 66.4 mmHg; 
PaCO,, 40.2 mmHg; and pH, 7.419 breathing room air. 
Parenteral administration of ampicillin was started and the 
patient became afebrile 2 days later. The CRP value and 
white blood cell count improved to 1.1 mg dl - ’ and 
8540 ,u-‘, respectively; however, improvements were 
incompletely observed on the auscultatory findings or chest 
roentgenogram. A transbronchial biopsy was carried out 
under a possible diagnosis of diffuse panbronchiolitis. As 
shown in Plate 2, the alveolar wall near the bronchiole was 
thickened due to the histiocytic accumulation and chronic 
inflammatory cell infiltrate composed of lymphocytes, 
plasma cells, and scattered eosinophils. The bronchial wall 
showed no serious changes except for a mild chronic 
inflammatory cell infiltrate. 
Under the diagnosis of DPB at an early stage, the 
administration of macrolide antibiotics (clarithromycin, 
400 mg day- ‘) was started. Six months later, he had 
another acute exacerbation of an airway infection and 
demonstrated the following levels at admission: CRP, 
4.2 mg dl - ‘; WBC 11 800 pl- ’ with 74% neutrophils, 25% 
lymphocytes, and 1% eosinophil. The parenteral admin- 
istration of cefmetazole effectively ameliorated this episode. 
The oral administration of macrolide antibiotics continued 
for a further year. However, the patient continued to 
complain of coughing, sputum production and no further 
